KKR deal in Gland Pharma calls for $100M plant investment

A key element of a plan by KKR to invest in India's Gland Pharma is to boost its manufacturing capacity, and so significantly increase its earnings potential. Citing unnamed sources, The Economic Times said investment firm KKR is looking to take on a 40% share in the small but rapidly growing Gland Pharma in a deal valued at about $500 million. The deal would include the buyout of an existing investor, Evolvence India Life Science Fund, and a cash infusion of between $95 million and $110 million to pump up manufacturing. Story